-
Je něco špatně v tomto záznamu ?
Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design
Z. Kejík, R. Kaplánek, P. Dytrych, M. Masařík, K. Veselá, N. Abramenko, D. Hoskovec, M. Vašáková, J. Králová, P. Martásek, M. Jakubek
Jazyk angličtina Země Švýcarsko
Typ dokumentu časopisecké články, přehledy
Grantová podpora
SVV260521
Charles University
UNCE 204064
Charles University
Progress Q26/LF1
Charles University
Progress Q27/LF1
Charles University
LM2018133 (EATRIS-CZ)
Ministry of Education Youth and Sports
RVO-VFN-64165/2012
Ministry of Health
TN01000013
Technology Agency of the Czech Republic
FW02020128
Technology Agency of the Czech Republic
NU21-08-00407
Ministry of Health
CZ.02.1.01/0.0/0.0/16_019/0000785
Operational Programme Research, Development and Education
NLK
Directory of Open Access Journals
od 2010
Free Medical Journals
od 2010
PubMed Central
od 2009
Europe PubMed Central
od 2009
ProQuest Central
od 2009-01-01
Open Access Digital Library
od 2009-01-01
Open Access Digital Library
od 2010-01-01
ROAD: Directory of Open Access Scholarly Resources
od 2009
- Publikační typ
- časopisecké články MeSH
- přehledy MeSH
Designing optimal (neo)adjuvant therapy is a crucial aspect of the treatment of non-small-cell lung carcinoma (NSCLC). Standard methods of chemotherapy, radiotherapy, and immunotherapy represent effective strategies for treatment. However, in some cases with high metastatic activity and high levels of circulating tumour cells (CTCs), the efficacy of standard treatment methods is insufficient and results in treatment failure and reduced patient survival. CTCs are seen not only as an isolated phenomenon but also a key inherent part of the formation of metastasis and a key factor in cancer death. This review discusses the impact of NSCLC therapy strategies based on a meta-analysis of clinical studies. In addition, possible therapeutic strategies for repression when standard methods fail, such as the administration of low-toxicity natural anticancer agents targeting these phenomena (curcumin and flavonoids), are also discussed. These strategies are presented in the context of key mechanisms of tumour biology with a strong influence on CTC spread and metastasis (mechanisms related to tumour-associated and -infiltrating cells, epithelial-mesenchymal transition, and migration of cancer cells).
BIOCEV 1st Faculty of Medicine Charles University 252 50 Vestec Czech Republic
Institute of Molecular Genetics Czech Academy of Sciences 142 20 Prague Czech Republic
Citace poskytuje Crossref.org
- 000
- 00000naa a2200000 a 4500
- 001
- bmc22001367
- 003
- CZ-PrNML
- 005
- 20220112153555.0
- 007
- ta
- 008
- 220107s2021 sz f 000 0|eng||
- 009
- AR
- 024 7_
- $a 10.3390/pharmaceutics13111879 $2 doi
- 035 __
- $a (PubMed)34834295
- 040 __
- $a ABA008 $b cze $d ABA008 $e AACR2
- 041 0_
- $a eng
- 044 __
- $a sz
- 100 1_
- $a Kejík, Zdeněk $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Technology, 166 28 Prague, Czech Republic
- 245 10
- $a Circulating Tumour Cells (CTCs) in NSCLC: From Prognosis to Therapy Design / $c Z. Kejík, R. Kaplánek, P. Dytrych, M. Masařík, K. Veselá, N. Abramenko, D. Hoskovec, M. Vašáková, J. Králová, P. Martásek, M. Jakubek
- 520 9_
- $a Designing optimal (neo)adjuvant therapy is a crucial aspect of the treatment of non-small-cell lung carcinoma (NSCLC). Standard methods of chemotherapy, radiotherapy, and immunotherapy represent effective strategies for treatment. However, in some cases with high metastatic activity and high levels of circulating tumour cells (CTCs), the efficacy of standard treatment methods is insufficient and results in treatment failure and reduced patient survival. CTCs are seen not only as an isolated phenomenon but also a key inherent part of the formation of metastasis and a key factor in cancer death. This review discusses the impact of NSCLC therapy strategies based on a meta-analysis of clinical studies. In addition, possible therapeutic strategies for repression when standard methods fail, such as the administration of low-toxicity natural anticancer agents targeting these phenomena (curcumin and flavonoids), are also discussed. These strategies are presented in the context of key mechanisms of tumour biology with a strong influence on CTC spread and metastasis (mechanisms related to tumour-associated and -infiltrating cells, epithelial-mesenchymal transition, and migration of cancer cells).
- 655 _2
- $a časopisecké články $7 D016428
- 655 _2
- $a přehledy $7 D016454
- 700 1_
- $a Kaplánek, Robert $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Technology, 166 28 Prague, Czech Republic
- 700 1_
- $a Dytrych, Petr $u 1st Department of Surgery-Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital, 121 08 Prague, Czech Republic
- 700 1_
- $a Masařík, Michal $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic
- 700 1_
- $a Veselá, Kateřina $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Technology, 166 28 Prague, Czech Republic
- 700 1_
- $a Abramenko, Nikita $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic
- 700 1_
- $a Hoskovec, David $u 1st Department of Surgery-Department of Abdominal, Thoracic Surgery and Traumatology, First Faculty of Medicine, Charles University and General University Hospital, 121 08 Prague, Czech Republic
- 700 1_
- $a Vašáková, Martina $u Department of Respiratory Medicine, First Faculty of Medicine, Charles University and Thomayer Hospital, 140 59 Prague, Czech Republic
- 700 1_
- $a Králová, Jarmila $u Institute of Molecular Genetics, Czech Academy of Sciences, 142 20 Prague, Czech Republic
- 700 1_
- $a Martásek, Pavel $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic
- 700 1_
- $a Jakubek, Milan $u Department of Paediatrics and Inherited Metabolic Disorders, First Faculty of Medicine, Charles University and General University Hospital, 128 08 Prague, Czech Republic $u BIOCEV, First Faculty of Medicine, Charles University, 252 50 Vestec, Czech Republic $u Department of Analytical Chemistry, Faculty of Chemical Engineering, University of Chemistry and Technology, 166 28 Prague, Czech Republic
- 773 0_
- $w MED00186380 $t Pharmaceutics $x 1999-4923 $g Roč. 13, č. 11 (2021)
- 856 41
- $u https://pubmed.ncbi.nlm.nih.gov/34834295 $y Pubmed
- 910 __
- $a ABA008 $b sig $c sign $y - $z 0
- 990 __
- $a 20220107 $b ABA008
- 991 __
- $a 20220112153551 $b ABA008
- 999 __
- $a ind $b bmc $g 1745454 $s 1152514
- BAS __
- $a 3
- BAS __
- $a PreBMC
- BMC __
- $a 2021 $b 13 $c 11 $e 20211105 $i 1999-4923 $m Pharmaceutics $n Pharmaceutics $x MED00186380
- GRA __
- $a SVV260521 $p Charles University
- GRA __
- $a UNCE 204064 $p Charles University
- GRA __
- $a Progress Q26/LF1 $p Charles University
- GRA __
- $a Progress Q27/LF1 $p Charles University
- GRA __
- $a LM2018133 (EATRIS-CZ) $p Ministry of Education Youth and Sports
- GRA __
- $a RVO-VFN-64165/2012 $p Ministry of Health
- GRA __
- $a TN01000013 $p Technology Agency of the Czech Republic
- GRA __
- $a FW02020128 $p Technology Agency of the Czech Republic
- GRA __
- $a NU21-08-00407 $p Ministry of Health
- GRA __
- $a CZ.02.1.01/0.0/0.0/16_019/0000785 $p Operational Programme Research, Development and Education
- LZP __
- $a Pubmed-20220107